TransCode Therapeutics Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers reporting preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study found that TTX-MC138 accumulated in metastatic bone lesions following systemic administration, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Repeated dosing was well tolerated with no observed systemic toxicity.

The findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology and suggest potential applicability across additional metastatic disease settings. This is particularly important because bone metastasis is a common and serious complication of advanced breast cancer, often leading to skeletal-related events and poor prognosis. Current treatments are largely palliative, underscoring the need for targeted therapies that can address the underlying metastatic process.

TTX-MC138 is designed to target miR-10b, a microRNA that is overexpressed in metastatic tumors and has been shown to promote invasion and metastasis. By inhibiting miR-10b, TTX-MC138 aims to restore the expression of tumor-suppressor genes such as HOXD10, thereby blocking the metastatic cascade. The positive results in this study add to a growing body of evidence supporting the therapeutic potential of targeting miR-10b.

“The survival benefit observed in this study is encouraging and highlights the potential of TTX-MC138 to address metastatic disease, which is the primary cause of cancer-related deaths,” said a spokesperson for TransCode. “We are excited about the implications for patients with advanced cancers, and we look forward to advancing this candidate through clinical development.”

TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress miR-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

The publication in Cancers is a significant milestone for TransCode, as it provides peer-reviewed validation of the company's technology platform. The study's findings also suggest that TTX-MC138 could be effective in other metastatic cancer types, expanding its potential market and clinical utility. As the company moves forward, these results will inform the design of future clinical trials and regulatory discussions.

For more information about TransCode Therapeutics and its pipeline, visit the company's newsroom at https://ibn.fm/RNAZ. The full press release can be viewed at https://ibn.fm/E6gbq.